Skip to Main Content

Paper Details

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.
Sci Rep
33
2019
AR, BET, BET bromodomain, BRD4, BRD4 target gene, MYC, androgen, androgen receptor, cancer, castration-resistant prostate cancer, cell lines, chromatin, prostate, prostate cancer, prostate cancer cell lines, tumor
Author NameAffiliation
Daniel J ColemanKnight Cancer Institute, Oregon Health & Science University
Lina GaoKnight Cancer Institute, Oregon Health & Science University
Jacob SchwartzmanKnight Cancer Institute, Oregon Health & Science University
James E KorkolaKnight Cancer Institute, Oregon Health & Science University
James E KorkolaOregon Health & Science University
David SampsonKnight Cancer Institute, Oregon Health & Science University
Joshua UrrutiaKnight Cancer Institute, Oregon Health & Science University
Carly J KingKnight Cancer Institute, Oregon Health & Science University
Carly J KingOregon Health & Science University
Kami E ChiottiKnight Cancer Institute, Oregon Health & Science University
Kami E ChiottiOregon Health & Science University
Laura M HeiserKnight Cancer Institute, Oregon Health & Science University
Laura M HeiserOregon Health & Science University
Laura M HeiserKnight Cancer Institute, Oregon Health & Science University
Laura M HeiserOregon Health & Science University
Joshi J AlumkalKnight Cancer Institute, Oregon Health & Science University
Joshi J AlumkalOregon Health & Science University
  • 1 - 17

Datasets

Release 1.2